⌘K
EDX Medical Group plc announced on 5 June 2026 that a general meeting will take place on 26 June 2026 at 2:00 p.m. at the Mezzanine Room, Royal Society of Medicine, 1 Wimpole Street, London. The Notice of General Meeting and Form of Proxy are being posted to eligible shareholders on 5 June 2026.
| Date | 5 Jun 2026 |
| Time | 07:00:03 |
| Category | AGMs and other meetings |
| ID | 1005H |
5 June 2026
EDX Medical Group plc
("EDX Medical" or the "Company")
Posting of Notice of General Meeting
CAMBRIDGE, UK: EDX Medical (AIM: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, announces that a general meeting will be held at the Mezzanine Room, Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE on 26 June 2026 at 2.00 p.m.
The Notice of General Meeting and Form of Proxy will be posted today, 5 June 2026, to eligible shareholders. Electronic copies will be shortly available on the Company's website at: https://edxmedical.co.uk/documents/
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.